Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Updates from the ENERGIZE study of mitapivat in non-transfusion-dependent alpha-/beta-thalassemia

Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, provides an update on the Phase III ENERGIZE trial (NCT04770779) investigating the safety and efficacy of mitapivat in patients with non-transfusion-dependent (NTD) alpha- or beta-thalassemia. The results are positive, with the study meeting its primary and secondary endpoints. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.